No Data
Express News | Porton Pharma Solutions and Aojin Life Sciences Announce Strategic Collaboration to Advance Xdc Conjugate Drugs for Dual Ind Filings in China and the U.S.
Porton Pharma Solutions and Aojin Life Sciences Announce Strategic Collaboration to Advance XDC Conjugate Drugs for Dual IND Filings in China and the U.S.
Porton pharma solutions (300363.SZ): plans to change part of the use of raised funds.
Gelonghui, December 10 – Porton Pharma Solutions (300363.SZ) announced that, given the significant changes in the main factors affecting the feasibility of the original fundraising project, and considering various factors such as the company's actual situation and development planning, in order to further improve the efficiency of the use of raised funds, the company intends to use the entire unused balance of the raised funds from the original investment project "Research and Development Center Construction Project for New Drug Outsourcing (Phase II)" (including the cumulative net interest income received, with a balance of 198.0161 million yuan as of November 30, 2024; the actual amount is subject to the amount in the special account on the day the funds are withdrawn) to permanently supplement liquidity.
Is Porton Pharma Solutions (SZSE:300363) A Risky Investment?
Porton Pharma Solutions Ltd.'s (SZSE:300363) 8.5% Gain Last Week Benefited Both Retail Investors Who Own 43% as Well as Insiders
Boteng shares: 2024 third quarter report
Porton Pharma Solutions Ltd.'s (SZSE:300363) Price Is Right But Growth Is Lacking
No Data
